Ambien CR

See also: Generic Ambien

Ambien CR is a brand name of zolpidem, approved by the FDA in the following formulation(s):

AMBIEN CR (zolpidem tartrate - tablet, extended release; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: September 2, 2005
  
  Strength(s): 12.5MG ^[RLD][AB], 6.25MG ^[AB]

Has a generic version of Ambien CR been approved?

A generic version of Ambien CR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ambien CR and have been approved by the FDA:

zolpidem tartrate tablet, extended release; oral

• 
  Manufacturer: ACTAVIS S ATLANTIC
  
  Approval date: October 13, 2010
  
  Strength(s): 6.25MG ^[AB]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: December 3, 2010
  
  Strength(s): 12.5MG ^[AB]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: April 14, 2011
  
  Strength(s): 6.25MG ^[AB]


• 
  Manufacturer: SANDOZ
  
  Approval date: July 1, 2011
  
  Strength(s): 12.5MG ^[AB], 6.25MG ^[AB]


• 
  Manufacturer: SYNTHON PHARMS
  
  Approval date: April 12, 2011
  
  Strength(s): 6.25MG ^[AB]


• 
  Manufacturer: SYNTHON PHARMS
  
  Approval date: June 6, 2011
  
  Strength(s): 12.5MG ^[AB]

ZOLPIDEM TATRATE (zolpidem tartrate tablet, extended release; oral)

• 
  Manufacturer: ACTAVIS S ATLANTIC
  
  Approval date: June 6, 2011
  
  Strength(s): 12.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ambien CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Controlled-release dosage forms comprising zolpidem or a salt thereof
  Patent 6,514,531
  Issued: February 4, 2003
  Inventor(s): Gérard; Alaux & Gareth; Lewis & Frédéric; Andre
  Assignee(s): Sanofi-Synthelabo
  The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.
  
  Patent expiration dates:
  
  
  • December 1, 2019
    
    ✓ 
    Drug product
  
  
  
  • June 1, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Ambien CR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Ambien CR Consumer Information (Cerner Multum)
• Ambien CR Advanced Consumer Information (Micromedex)
• Zolpidem Consumer Information (Drugs.com)
• Zolpidem Consumer Information (Wolters Kluwer)
• Zolpidem Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Zolpidem Oral Spray Consumer Information (Wolters Kluwer)
• Zolpidem Consumer Information (Cerner Multum)
• Zolpidem Oral, Oromucosal Advanced Consumer Information (Micromedex)
• Zolpidem Tartrate AHFS DI Monographs (ASHP)

GastroMARK

GastroMARK is a brand name of ferumoxsil, approved by the FDA in the following formulation(s):

GASTROMARK (ferumoxsil - suspension; oral)

• 
  Manufacturer: AMAG PHARMS INC
  
  Approval date: December 6, 1996
  
  Strength(s): EQ 0.175MG IRON/ML ^[RLD]

Has a generic version of GastroMARK been approved?

No. There is currently no therapeutically equivalent version of GastroMARK available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of GastroMARK. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with GastroMARK.

See also...

• GastroMARK Consumer Information (Cerner Multum)
• Ferumoxsil Consumer Information (Cerner Multum)

Silimarina Genfar

Silimarina Genfar may be available in the countries listed below.

Ingredient matches for Silimarina Genfar

Silibinin

Silibinin is reported as an ingredient of Silimarina Genfar in the following countries:

• Colombia


• Ecuador

International Drug Name Search

Calcitonine Pharmy II

Calcitonine Pharmy II may be available in the countries listed below.

Ingredient matches for Calcitonine Pharmy II

Calcitonin

Calcitonin is reported as an ingredient of Calcitonine Pharmy II in the following countries:

• France

International Drug Name Search

Dacten

Dacten may be available in the countries listed below.

Ingredient matches for Dacten

Candesartan

Candesartan cilexetil (a derivative of Candesartan) is reported as an ingredient of Dacten in the following countries:

• Argentina

International Drug Name Search

Diazepam AbZ

Diazepam AbZ may be available in the countries listed below.

Ingredient matches for Diazepam AbZ

Diazepam

Diazepam is reported as an ingredient of Diazepam AbZ in the following countries:

• Germany

International Drug Name Search

Apo-Flavoxate

Apo-Flavoxate may be available in the countries listed below.

Ingredient matches for Apo-Flavoxate

Flavoxate

Flavoxate hydrochloride (a derivative of Flavoxate) is reported as an ingredient of Apo-Flavoxate in the following countries:

• Canada


• Hong Kong

International Drug Name Search

Aloric

Aloric may be available in the countries listed below.

Ingredient matches for Aloric

Allopurinol

Allopurinol is reported as an ingredient of Aloric in the following countries:

• Bangladesh

International Drug Name Search

Aminocer

Aminocer may be available in the countries listed below.

Ingredient matches for Aminocer

Levocarnitine

Levocarnitine tartrate (a derivative of Levocarnitine) is reported as an ingredient of Aminocer in the following countries:

• Greece

International Drug Name Search

Nifedel

Nifedel may be available in the countries listed below.

Ingredient matches for Nifedel

Nifedipine

Nifedipine is reported as an ingredient of Nifedel in the following countries:

• Argentina

International Drug Name Search

Dovobet

In the US, Dovobet (betamethasone topical) is a member of the drug class topical antipsoriatics and is used to treat Psoriasis.

US matches:

• Dovobet

UK matches:

• Dovobet Ointment
• Dovobet gel (SPC)
• Dovobet Ointment (SPC)

Ingredient matches for Dovobet

Betamethasone

Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Dovobet in the following countries:

• Belgium


• Canada


• Greece


• Ireland


• Italy


• Luxembourg


• Netherlands


• South Africa


• United Kingdom

Calcipotriol

Calcipotriol is reported as an ingredient of Dovobet in the following countries:

• Canada


• Greece


• Luxembourg


• South Africa

Calcipotriol monohydrate (a derivative of Calcipotriol) is reported as an ingredient of Dovobet in the following countries:

• Ireland


• Italy


• Netherlands


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.